Cost-utility Analysis of the EOX Drug Regimen versus the DCF Drug Regimen for Patients with Advanced Gastric Cancer
Journal Title: Middle East Journal of Cancer - Year 2019, Vol 10, Issue 2
Abstract
Background: Cancer is one of the major causes of mortality and as an effective factor in the burden of diseases for the future. Among all cancers, gastric cancer is the fourth most common and the second leading cause of cancer mortality worldwide. In this study, we aim to evaluate the cost-utility of two chemotherapy regimens – epirubicin, oxaliplatin, and capecitabine versus docetaxel, cisplatin, and fluorouracil in patients with advanced gastric cancer in a hospital in southern Iran. Method: This cross-sectional study was an economic evaluation of cost-utility type that included all patients at Amir Hospital (Shiraz, Iran) who had advanced gastric cancer and received either the epirubicin, oxaliplatin, and capecitabine or docetaxel, cisplatin, and fluorouracil chemotherapy regimen. All costs and the quality-adjusted life years were calculated, followed by one-way sensitivity analysis to verify the results. Results:A total of 54 patients participated in this study, amongst whom 20 received the epirubicin, oxaliplatin, and capecitabine regimen and 34 received the docetaxel, cisplatin, and fluorouracil regimen. The mean quality of life of patients that received docetaxel, cisplatin, and fluorouracil was 0.747, whereas it was 0.836 for patients that received epirubicin, oxaliplatin, and capecitabine. The docetaxel, cisplatin, and fluorouracil treatment group ($5573) was more expensive than the epirubicin, oxaliplatin, and capecitabine group ($3108). The results obtained from the cost-utility analysis showed that the epirubicin, oxaliplatin, and capecitabine drug regimen was costeffective due to lower cost and higher utility than the docetaxel, cisplatin, and fluorouracil regimen. One-way sensitivity analysis confirmed the accuracy of these results. Conclusion: Due to the cost-effectiveness of the epirubicin, oxaliplatin, and capecitabine drug regimen compared to docetaxel, cisplatin, and fluorouracil, we recommend that oncologists use this regimen to treat gastric cancer patients.
Authors and Affiliations
Mohammad Javad Khezeli, Mehdi Dehghani, Khosro Keshavarz, Zahra Kavosi
Keywords
Related Articles
- EP ID EP638882
- DOI 10.30476/mejc.2019.78513.
- Views 95
- Downloads 0
Analysis of EVI1 Gene Expression in Acute Myeloid Leukemia Patients in the Northeast of Iran
Background: Acute myeloid leukemia (AML) is a heterogeneous disease characterized by increasing immature blood cells in the bone marrow. Aberrant expression of specific genes is a common finding in AML. The proto-oncogen...
Survey of Neutrophil to Lymphocyte Ratio as Prognostic Factor in Colorectal Cancer
Background: Neutrophil-lymphocyte ratio (NLR) is derived from the neutrophil and lymphocyte count obtained from routine complete blood count with the differential test (CBC/diff). The aim of the present study is to deter...
An Immunohistochemical Study of Vascular Endothelial Growth Factor Expression in Meningioma and Its Correlation with Tumor Grade
Background: Meningiomas are one of the most common primary brain tumors and the most common intradural spinal tumors. Vascular endothelial growth factor has been demonstrated to play an important role in the stimulation...
Evaluation of Promoter Hypermethylation of Tumor-Suppressor Genes p14 and p16 in Iranian Endometrial Carcinoma Patients
Background: Endometrial cancer is a common gynecological malignancy with good prognosis in the early stages of the disease. The CpG island in the promoter region of tumor-suppressor genes are frequently methylated in var...
Examining the Predictive Role of Emotional Self-Regulation in Quality of Life and Perception of Suffering among Patients with Breast Cancer
Background: Breast cancer is the most common type of cancer and second leading cause of death in women after lung cancer. The World Health Organization has reported that breast cancer, with 502,000 deaths in 2005, surpas...